First the US, now the EU: Pfizer’s 20-valent pneumococcal jab for infants headed to regulators
About five weeks after Pfizer said its 20-valent vaccine follow-up to Prevnar 13 was effective in infants in a US study, the Big Pharma now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
